On March 22, 2007, McInally, Thomas; Thom, Stephen; Wada, Hiroki published a patent.Product Details of 142327-44-4 The title of the patent was Purine derivatives having immunomodulating properties. And the patent contained the following:
Purine derivatives, such as I [R = amino group, such as NMe2 or NHMe, or a N-bound nitrogen containing heterocycle, such as 1-pyrrolidinyl or 4-methyl-1-piperazinyl; X = alkylene linking group, such as (CH2)m, m = 3, 4; X1 = alkylene linking group, such as (CH2)n, n = 2, 3], were prepared for use in immunomodulating pharmaceutical compositions which are useful in the treatment of diseases or conditions in which modulation of TLR7 activity is beneficial. These diseases or conditions may include allergic or viral diseases, cancers, asthma, COPD, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis B, hepatitis C, HIV, HPV, bacterial infections and dermatosis. Thus, purine derivative I [R = NMe2, X = X1 = (CH2)3] was prepared in 10 steps starting from 2,6-dichloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine, BuONa, Br(CH2)3Br, H2N(CH2)3OH, and BrCH2-3-C6H4CH2CO2Me. The prepared purine derivatives were tested for interferon inducing activity in rat spleen cells and for activation of recombinant human TLR7. The experimental process involved the reaction of Methyl 2-(3-formylphenyl)acetate(cas: 142327-44-4).Product Details of 142327-44-4
The Article related to purine derivative preparation immunomodulator toll like receptor activity, Biomolecules and Their Synthetic Analogs: Others, Including Purines, Pyrimidine Nucleic Acid Bases, Flavins, Lignans and other aspects.Product Details of 142327-44-4
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics